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Recent  advances  of  rotavirus  (RV)  basic  and  applied  research  are  reviewed.  They  consist  of  determination
of  the  RV  particle  structure  and functions  of structural  proteins,  classiﬁcation  into  genotypes  based  on
whole  genome  analyses,  description  of  the  RV genome  and  gene  protein  assignments,  description  of  the
viral  replication  cycle  and  of functions  of  RV-encoded  non-structural  proteins  as  well  as  cellular  pro-
teins  and  cellular  organelles  involved,  the  present  status  of  RV  genetics  and  reverse  genetics,  molecular
determinants  of  pathogenesis  and  pathophysiology,  the  RV-speciﬁc  humoral  and cell-mediated  immune
responses,  innate  immune  responses  and correlates  of  protection,  laboratory  diagnosis,  differential  diag-otavirus
tructure–function studies
eplication cycle
athogenesis
mmune responses and correlates of
rotection
nosis and  present  status  of  treatment,  the  molecular  epidemiology  and  mechanisms  of  evolution  of RVs,
the  development  and  universal  application  of  RV  vaccines  as well  as issues  arising  from  present  universal
RV  vaccination  programs  and  work  on alternative  vaccines.  The  review  concludes  by presenting  problems
requiring  further  exploration  and  perspectives  of future  basic  and  translational  research.
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. Introduction
Rotaviruses (RVs) were recognized as a major cause of acute gas-
roenteritis (AGE) in infants and young children in 1973 (Bishop
t al., 1973; Flewett et al., 1973). Before that year RVs had
lready been discovered in diarrheic mice (Adams and Kraft, 1963),
onkeys (Malherbe and Harwin, 1963) and cattle (Mebus et al.,
969) and since then in the young of many mammalian species
ncluding bats (Estes and Greenberg, 2013; He et al., 2013) and also
n birds (Kindler et al., 2013; Otto et al., 2012; Trojnar et al., 2009).
uring the last 40 years an enormous amount of basic research on
V structure, replication, pathogenesis and immune responses has
ccumulated. Due to modern diagnostic techniques the molecular
pidemiology of RVs has been extensively explored. Recently, two
ive attenuated RV vaccines have been licensed in many countries
nd are increasingly being applied in universal vaccination pro-
rams. In the following I will attempt to give an up-to-date review
f important recent achievements in research and prevention and
o formulate remaining open questions and perspectives.
. Structure
The fully infectious RV particle (=virion) consists of 3 protein
ayers and is also termed triple-layered particle (TLP). By electron
icroscopy, TLPs resemble wheels (lat. rota), and this appearance
as led to the name of Rotavirus for the genus (Flewett et al., 1974).
ased on cryo-electron microscopy and image reconstruction data
reviewed by Jayaram et al., 2004), the following structure of icosa-
edral symmetry has been recognized: the single layered particle
SLP = core shell) is formed by 120 molecules of the viral protein
 (VP2), arranged as 60 dimers in a T = 1 symmetry (Fig. 1C). Five
f the dimers form a decamer around the ﬁvefold symmetry axis,
nd 12 decamers make up the core protein layer which is uniform
xcept for small pores along the ﬁvefold axis (McClain et al., 2010).
 ‘ﬁvefold hub’ (density) projecting into the core interior along the
vefold axis was ﬁrst thought to be contributed by the N-terminus
f VP2 (McClain et al., 2010), but was more recently recognized
o result from the VP1 structure (Estrozi et al., 2013). Replication
nzyme complexes, consisting of VP1 and VP3, are located at the
nside of the core at the axis of ﬁvefold symmetry (Fig. 1C and
) opposite the class I channels (McClain et al., 2010; Trask et al.,
012a, 2012b; Estrozi et al., 2013) and are in intense contact with
ne particular dedicated genomic dsRNA segment via VP1 (Periz
t al., 2013). The core shell encloses the viral genome of 11 seg-
ents of dsRNA as well as the viral RNA dependent RNA polymerase
RdRp), VP1 and the capping enzyme, VP3.
The genomic RNA segments have been proposed to form
onical cylinders around the replication complexes (Prasad et al.,
996; Jayaram et al., 2004) (Fig. 1D) but details of the dsRNA
tructure within the core are just beginning to be explored. Thus,
n actively transcribing double-layered particles (DLPs, see below),
 decreased order of the middle (VP6) layer was found to be accom-
anied by increased order of the core content (Kam et al., 2014).
imilar partial order of dsRNA segments was observed in core par-
icles of bluetongue virus (Gouet et al., 1999). The 11 RNA segments
Fig. 1A) have very short completely conserved 5′ and 3′ terminal
ucleotide (nt) sequences, 5′-GGC · · · ACC-3′. The untranslated
egions (UTR) of the RNA segments (+ sense) are small: 9–48 nt
t the 5′ end, and 17–182 nt at the 3′ end. The 5′ and 3′ ends are
f partial inverted complementarity and are subject to long range . . . .  .  . .  . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . . . . .  .  . . .  . . . .  . .  .  .  . . . .  .  .  . . . . .  . . .  .  .  .  . . . .  .  . . . . .  87
interactions (LRI) (Tortorici et al., 2006; Li et al., 2010). Those at the
3′ end function as RdRp recognition signals (Tortorici et al., 2003)
and also interact with NSP3 (Chizhikov and Patton, 2000; Vende
et al., 2000), involved in activation of translation (see below). The
RdRp structure has been solved at a resolution of 2.9 A˚ (Lu et al.,
2008) (Fig. 2): VP1 forms a cage-like structure disrupted by 4
tunnels (leading to the catalytic site in the center of the molecule)
which are proposed to allow for: (1) the entry of free nucleoside
triphosphates (NTPs), (2) the entry of template ssRNA, (3) the exit
of the (+) ssRNA product, and (4) the exit of (−) ssRNA (transcrip-
tion) or dsRNA (replication). Tunnel 3 is positioned toward the
class I channel inside of VP2 (Settembre et al., 2011; Estrozi et al.,
2013), permitting release of (+) RNAs into the cytoplasm; tunnel
4 directs the newly replicated dsRNA toward the core interior.
Analysis of different VP1-polyribo-oligonucleotide complexes has
resulted in the ﬁnding that the 5′-UGUG-3′ sequence at the 3′ end
of the RNA is speciﬁcally recognized at the template entry channel
(Lu et al., 2008). In many aspects the structure of the RV RdRp is
similar to the corresponding enzyme of orthoreovirus (Tao et al.,
2002).
The viral core is surrounded by 260 trimers of VP6, which
form the middle layer and constitute double-layered particles
(DLPs) (Fig. 1C and E). The VP6 structure has also been determined
(Mathieu et al., 2001): VP6 trimers make contact with both the
underlying core (VP2) (Charpilienne et al., 2002) as well as VP7 and
VP4 trimers on the outside.
The DLPs in turn are covered by 260 trimers of VP7 and 60
spikes of VP4 trimers (=180 molecules) to form the TLPs (Fig. 1B
and C). The virions contain 132 channels along the axes of ﬁve-
fold (12 channels of class I), threefold and twofold symmetry (60
class II and 60 class III channels, respectively) (Jayaram et al., 2004).
The three-dimensional (3D) structure of the RV virion has recently
been determined by electron cryomicroscopy (cryoEM) and single-
particle tomography at about 4.3 A˚ resolution (Settembre et al.,
2011): there is an intense interaction of the VP4 trimer with
both VP6 (into which the base of VP5* is half buried) and VP7
(Fig. 3). The structure and interactions of VP4 with other struc-
tural RV proteins permit the description of a mechanism of RV
entry (see below). It has previously been shown that VP4 trimers
can only be observed by cryo-EM in TLPs grown in the pres-
ence of trypsin (Crawford et al., 2001). Since the stoichiometry
of VP4 in RVs grown in the presence and absence of trypsin is
identical, it was concluded that VP4 spikes of RV grown in the
absence of trypsin are icosahedrally disordered. By single particle
cryo-EM and cryo-electron tomography (cryo-ET) it has recently
been demonstrated for 2 RV strains that the VP4 spike structure of
RV particles grown in the absence of trypsin is indistinguishable
from that of particles grown in the presence of trypsin (Rodríguez
et al., 2014), suggesting that the previous lack of observation of VP4
structures in trypsin-free grown RV particles was mainly due to the
imposition of icosahedral structure requirements on the previous
cryo-EM data and that proteolytic cleavage of VP4 mainly achieves
conformational changes enabling viral entry into cells. As an aside,
the science of structural biology is closely related to talents in visual
arts as noted by Stephen and Baumeister (2008).3. Classiﬁcation
Rotaviruses constitute the genus Rotavirus, one of the 15 genera
of Reoviridae family which is subdivided into the sub-families of
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Fig. 1. Aspects of rotavirus structure. (A) PAGE gel showing 11 dsRNA segments comprising the rotavirus (RVA) genome. The gene segments are numbered on the left and
the  proteins they encode are indicated on the right. (B) Cryo-EM reconstruction of the rotavirus triple-layered particle. The spike protein VP4 is colored in orange and the
outermost VP7 layer in yellow. (C) A cutaway view of the rotavirus TLP showing the inner VP6 (blue) and VP2 (green) layers and the transcriptional enzymes (in red) anchored
to  the inside of the VP2 layer at the ﬁvefold axes. (D) Schematic depiction of genome organization in rotavirus. The genome segments are represented as inverted conical
spirals  surrounding the transcription enzymes (shown as red balls) inside the VP2 layer in green. (E and F) Model from Cryo-EM reconstruction of transcribing DLPs. The
endogenous transcription results in the simultaneous release of the transcribed mRNAs from channels located at the ﬁvefold vertices of the icosahedral DLP.
From Jayaram et al. (2004). With permission of the authors and the publisher.
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mig. 2. Structure of the RV RdRp VP1. Surface rendering (A) of the complete VP1 po
n  pink, and the C-terminal plug is in cyan. (B) Sagittal cutaway of the image in (A), a
rom Lu et al. (2008). With permission of the authors and the publisher.
he Sedoreovirinae (genera Cardoreovirus,  Mimoreovirus,  Orbivirus,
hytoreovirus, Rotavirus, Seadornavirus)  and the Spinareovirinae
genera Aquareovirus, Coltivirus, Cypovirus,  Dinovernavirus, Fijivirus,
dnoreovirus, Mycoreovirus, Orthoreovirus,  Oryzavirus). According
o the serological reactivity and genetic variability of VP6, at
east 8 different groups, also termed species, are differentiated
termed RVA-RVH) (Matthijnssens et al., 2012). The RVA species
omprises at least 27 G types (according to the nt sequence
f VP7) and 37 P types (according to the nt sequence of VP4)
Matthijnssens et al., 2011a; Rotavirus Classiﬁcation Working
roup, 2013). For G types, serotypes and genotypes are synony-
ous, e.g. G1, G2, etc. For P types, there are many more P genotypeside chain. The N-terminal domain is in yellow, the C-terminal (bracelet) domain is
tation to the left by 90◦ , showing the four tunnels extending into the central cavity.
than reference sera determining P serotypes: therefore, a double
nomenclature has been introduced, e.g. P1A[8] designating the P
serotype 1A and P genotype 8, etc. (Estes and Greenberg, 2013).
A comprehensive, nt sequence-based classiﬁcation comprising
the complete genome has been introduced for RVAs, in which the
VP7–VP4–VP6–VP1–VP2–VP3–NSP1–NSP2–NSP3–NSP4–NSP5/6
genotypes are identiﬁed and differentiated according to particular
cut-off points of nt sequence identities (Matthijnssens et al.,
2008a, 2008b, 2011a; Maes et al., 2009). Table 1 demonstrates the
enormous degree of genomic diversity among RVAs co-circulating
in different population groups and animals at various times.
Recently, similar comprehensive genotype differentiations for
78 U. Desselberger / Virus Resea
Fig. 3. Interaction of rotavirus structural proteins. Cutaway view of the interactions
of VP4 within the TLP. VP8* is in magenta and VP5* is in red. The VP5* segment
that will form the coiled coil (c-c) in the ‘post-entry’ conformation is in cyan. The
globular foot domains of the VP5* is anchored at a six-coordinated position in the
VP6 layer (green); a VP7 trimer (yellow) caps each trimer of VP6. Both form surface
lattices in T = 13 levo icosahedral symmetry. The VP6 lattice overlays the VP2 shell
(dark blue), which surrounds the coiled RNA genome (not shown).
From Settembre et al. (2011). With permission of the authors and the publisher.
Table 1
Genotypes of species A rotaviruses.
RV protein Percent
identitya
Number of
genotypesb
Genotype (acronym
underlined)
VP7 80 27G Glycosylated
VP4  80 37P Protease-sensitive
VP6  85 18I Inner capsid
VP1 83 9R RdRpc
VP2 84 9C Core protein
VP3  81 8M Methyltransferase
NSP1 79 19A Interferon Antagonist
NSP2 85 10N NTPase
NSP3 85 12T Translation enhancer
NSP4 85 15E Enterotoxin
NSP5 91 11H PHosphoprotein
Updated from Matthijnssens et al. (2008a, 2008b).
a Nucleotide percent identity cut off value deﬁning genotypes.
b
S
R
2
4
s
n
g
mOctober 2013 (Rotavirus Classiﬁcation Working Group, 6th meeting, Valencia/
pain).
c RNA-dependent RNA polymerase.
VBs and RVCs have started to be established (Marthaler et al.,
012, 2013).
. The rotavirus genome and gene-protein assignments
The RVA genome is approximately 18,500 bp in size and con-
ists of 11 segments of dsRNA which encode 6 structural and 6
on-structural proteins. The genes are monocistronic, except for
enome segment 11, which encodes two proteins. The gene seg-
ents are between 667 and 3302 bp in length. The gene-proteinrch 190 (2014) 75–96
and protein-function assignments have been determined for sev-
eral RVA strains and are shown for the bovine RVA RF (G6P6[1])
strain in Table 2. Besides the 6 structural proteins described
above (VP1, VP2, VP3, VP4, VP6, VP7), 5–6 non-structural pro-
teins (NSP1–NSP5/6) are produced the functions of which will be
described below. RVCs do not encode an NSP6.
The differences at the 3′ end of the RNAs between different RV
species are considered to be the reason for their lack of reassort-
ment (see below). The short 5′ and 3′ UTRs are not long enough to
singly contain the putative packaging sequences important for RV
morphogenesis, but direct experimental evidence is so far missing
due to the lack of a tractable reverse genetics system for RVs (see
below). The packaging signals of the RNA segments of inﬂuenza
viruses and as far as explored of the orbiviruses include sequences
of parts of the UTRs and the adjacent ORFs (Essere et al., 2013;
Matsuo and Roy, 2009).
Rotavirus genes can be ‘rearranged’, due to partial nt duplica-
tions or deletions of RNA segments generated by special forms of
intragenic recombination (Desselberger, 1996). Rotaviruses with
rearrangements in 3 genes were found to package approximately
1800 additional bp of RNA, i.e. about 10% of the genome, to be
replication competent and to be physically and genetically stable
(Hundley et al., 1987; McIntyre et al., 1987). Genome rearrange-
ments can be experimentally reproduced by serial passage of RVs
in cell culture at high MOI  (Hundley et al., 1985).
5. The rotavirus replication cycle
The RV replication cycle (Fig. 4) includes the following steps:
- attachment, mediated by VP4 and VP7
-  penetration and uncoating
- plus strand ssRNA (=mRNA) synthesis, mediated by VP1, VP3 and
VP2
- viroplasm formation, mediating RNA packaging, minus strand
RNA synthesis (=RNA replication) and DLP formation
- Virus particle maturation (to TLPs) and release
5.1. Virus particle attachment
RV attachment is a complex process (López and Arias, 2004).
First, the infectious RV particle, the TLP, interacts by its VP4
spikes with cellular receptors (attachment receptors). The recep-
tors contain sialic acid (SA) in terminal or sub-terminal positions.
For the rhesus RV VP4 the SA binding site has been structurally
identiﬁed (Dormitzer et al., 2002a, 2002b). Treatment of cells by
neuraminidase abolishes infection by certain RV strains (e.g. SA11)
which have therefore been called SA-sensitive strains (Isa et al.,
2006). Other strains which can infect neuraminidase-treated cells,
have initially been termed ‘SA-resistant’ strains (e.g. Wa  and DS-1)
but were then shown to bind to receptors containing SA in inter-
nal position of glycolipids which are insensitive to neuraminidase
treatment, e.g. the GM1  ganglioside (Guo et al., 1999; Haselhorst
et al., 2009). On the virus side, attachment is mediated by the
VP8* subunit of VP4: a shallow groove of the VP8* surface inter-
acts with SAs on cellular glycans (Dormitzer et al., 2002a, 2002b).
More recently it has been demonstrated that certain RV strains, e.g.
G10P[11], bind to non-SA containing histo blood group antigens
(HBGA) via the Gal1–4GlcNAc motif (Hu et al., 2012; Huang et al.,
2012; Ramani et al., 2013). For the P[8] genotype it has been shown
that its interaction with HBGA receptor depends on a functioning
FUT2 enzyme (Imbert-Marcille et al., 2014). Interestingly, certain
RVs and noroviruses both use polymorphic HBGA receptors for
attachment (Tan and Jiang, 2014; Le Pendu et al., 2014). Various cel-
lular surface molecules can act as (post-attachment) co-receptors,
U. Desselberger / Virus Research 190 (2014) 75–96 79
Table  2
Gene-protein assignments, protein localization and protein-function assignment adapted to bovine rotavirus RF strain (G6P6[1]).
Genome segment Size (bp) Encoded protein Size (kDa) Location in virion Molecules/virion Functions
1 3302 VP1 125 Core 12 RdRp; ssRNA binding; complex with VP3
2  2687 VP2 94 Core 120 Core shell; RNA binding; required for RdRp activity
3  2592 VP3 88 Core 12 Guanylyltransferase; methyltransferase;
2′ ,5′-phosphodiesterase; ssRNA binding; complex with
VP1
4  2362 VP4a 86 Outer layer 180 Homotrimer; P type neutralization antigen;
attachment protein; protease enhanced infectivity;
virulence; fusion with cell membrane
5  1581 NSP1 58 Nonstructural Interferon antagonist; E3 ligase; RNA binding
6  1356 VP6 44 Middle layer 780 Homotrimer, species determinant; protection
(intracellular neutralization); required for
transcription
7  1062 VP7b 37 Outer layer 780 Homotrimer; glycoprotein; G type neutralization
antigen; Ca2+ dependent
8  1059 NSP2 36 Nonstructural Octamer; binds RNA, NTPase; NDP kinase; helix
destabilizing; essential for viroplasm formation
9  1074 NSP3 34 Nonstructural Dimer; binds to: 3′ terminus of viral ss (+) RNA, cellular
eIF4G, Hsp90; displaces PABP; inhibits host protein
translation
10  751 NSP4 20 Mainly nonstructural Very few RER transmembrane glycoprotein; viroporin;
intracellular receptor for DLPs; interacts with
viroplasms and autophagy pathway; modulates
intracellular Ca2+ and RNA replication; enterotoxin
(secreted); virulence
11  666 NSP5 21 Nonstructural Dimer; phospho- and O-glycosylated protein; RNA
binding; kinase; essential for viroplasm formation;
interaction with VP2
NSP6c 12 Nonstructural Interaction with NSP5, localized in viroplasm
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b Signal peptide cleaved off.
c Second ORF of RNA11.
uch as several integrins (21, 3, x2, 41), which react
ith integrin ligand motifs on VP5* or VP7 (motif DGE on VP5* or
otifs GPR and CNP on VP7) (Coulson et al., 1997; Graham et al.,
003; Zárate et al., 2004; Gutiérrez et al., 2010), or with the human
eat shock cognate protein 70 (Hsc70) (Guerrero et al., 2002; Zárate
t al., 2003; Pérez-Vargas et al., 2006). All co-receptors are asso-
iated with lipid rafts, i.e. detergent-resistant lipids close to the
ellular plasma membrane acting as platforms on which RV TLPs
ssociate (Isa et al., 2004). The relative importance of the vari-
us receptors for human RV infection is beginning to be assessed
Fleming et al., 2014).
It should be noted that some RV strains hemagglutinate (Kalica
t al., 1978; Bastardo and Holmes, 1980) and that it is the VP8*
omponent of VP4 (at the tip of the spikes) which mediates this
nteraction (Mackow et al., 1989; Fiore et al., 1991).
.2. Virus particle penetration and uncoating
Before trypsin cleavage, VP4 spikes are ﬂexible and thus not vis-
ble by EM,  although they are present in a virtually identical struc-
ure as recently conﬁrmed by single particle cryo-ET (Rodríguez
t al., 2014). Upon contact with the cellular receptor, the VP4 spikes
f RV TLPs undergo conformational changes in such a way that the
ipophilic domains of VP5* which are normally hidden below VP8*
re exposed on the surface in form of a ‘post-penetration umbrella’
onformation (Kim et al., 2010; Trask et al., 2010a; Settembre et al.,
011). Treatment of RV particles with trypsin seems to favor this
ransition (Crawford et al., 2001; Rodríguez et al., 2014) and convey
ull infectivity to the TLPs (Estes et al., 1981). Partially trypsin-
esistant RV mutants were shown to have a delay in cellular entry,
ut then to replicate as well as wildtype (wt) virus (Trask et al.,
013). Following binding, the mechanism of cell penetration of RV
articles remains unclear; it may  occur by receptor-mediated endo-
ytosis or direct membrane penetration, with solubilization of the
uter capsid proteins due to low Ca2+ concentrations in endosomes(Ludert et al., 1987) to yield DLPs. The presence of cholesterol and of
the GTPase dynamin on cell membranes are required for RV entry,
but not for all RV strains (Sánchez-San Martín et al., 2004). Genome-
wide RNAi screening revealed that components of the ‘endosomal
sorting complex for transport’ (ESCRT) are involved in RV entry
(Silva-Ayala et al., 2013). RV strains differ in the usage of endo-
somal pathways; some require Rab7-mediated transport to late
endosomes (Díaz-Salinas et al., 2014).
5.3. RV plus strand (m)RNA synthesis
RV particles possess their own transcription complexes (TCs),
consisting of VP1, the viral RNA-dependent RNA polymerase
(RdRp), and VP3, the viral capping enzyme (with phosphodieste-
rase, guanylyltransferase and methylase activities). The TCs are
localized at the inner surface of the VP2 (core) layer at the ﬁve-
fold symmetry axes, i.e. at 11 or 12 vertices (Jayaram et al., 2004).
Each TC is complexed with a dedicated viral RNA segment (Periz
et al., 2013). Rotavirus DLPs in cytoplasm produce capped, non-
polyadenylated, (+) ssRNA transcripts (from the negative strand of
the genomic RNA) which are released from the particle through the
class I channels (Fig. 1E and F). The transcripts serve either for trans-
lation of virus-encoded proteins (early in the replication cycle) or as
templates for replication (late in the replication cycle) to become
the dsRNA genomes of RV progeny (Silvestri et al., 2004). Parti-
cles of the Reoviridae family can produce mRNAs of a maximum
of 12 different genomic segments (e.g. in the genus Coltivirus). For
the Rotavirus (11 genomic RNA segments) and Orthoreovirus (10
genomic RNA segments) genera it is not clear whether the 1–2
‘extra’ TCs are occupied by RNAs or are ‘empty’. RV DLPs are ‘tran-
scriptionally active’ in the cellular cytoplasm and in vitro, where
they produce large amounts (in mg  range) of mRNAs, provided pre-
cursors and an energy source (ATP) are in sufﬁcient supply (Cohen
et al., 1979; Spencer and Arias, 1981; Lawton et al., 1997; Lu et al.,
2008). A logarithmic increase in mRNA production at later stages
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Fig. 4. The rotavirus replication cycle. The rotavirus triple layered particles (TLPs) ﬁrst attach to sialo-glycans (or histo-blood group antigens) on the host cell surface, followed
by  interactions with other cellular receptors, including integrins and Hsc70. Virus is then internalized by receptor-mediated endocytosis. Removal of the outer layer, triggered
by  the low calcium of the endosome, results in the release of transcriptionally active double-layered particles (DLPs) into the cytoplasm. The DLPs start rounds of mRNA
transcription, and these mRNAs are used to translate viral proteins. Once enough viral proteins are made, the RNA genome is replicated and packaged into newly made DLPs
in  specialized structures called viroplasms, which interact with lipid droplets. The newly made DLPs bind to NSP4, which serves as an endoplasmic reticulum (ER) receptor,
and  bud into the ER. NSP4 also acts as a viroporin to release Ca2+ from intracellular stores. Transiently enveloped particles are seen in the ER. The transient membranes are
removed as the outer capsid proteins VP4 and VP7 assemble, resulting in the maturation of the TLPs. The progeny virions are released through cell lysis. In polarized epithelial
cells,  particles are released by a non-classical vesicular transport mechanism. For further details see text.
From Estes and Greenberg (2013). With permission of the authors and the publisher.
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hf infection (>4 h p.i.) indicates that the newly synthesized DLPs
ave become transcription active (secondary transcription) (Stacy-
hipps and Patton, 1987; Ayala-Breton et al., 2009). Rotavirus
egment-speciﬁc mRNAs extruded from DLPs are then translated
nto the encoded proteins in the cytoplasm (see above and Table 2).
.4. Viroplasm formation
Rotavirus proteins and RNAs interact speciﬁcally in cytoplasmic
nclusion bodies termed ‘viroplasms’. In order for viroplasms
o form, the presence of two of the RV non-structural proteins,
SP2 and NSP5, is essential and sufﬁcient, since co-expression
f NSP2 and NSP5 in uninfected cells leads to the production of
iroplasm-like structures (Fabbretti et al., 1999). Blockage of these
wo proteins by speciﬁc siRNAs, intrabodies or the use of NSP2- or
SP5-speciﬁc RV ts mutants at the non-permissive temperature
revent viroplasm formation, RV morphogenesis and the pro-
uction of infectious RV progeny (Silvestri et al., 2004; Vascotto
t al., 2004; Campagna et al., 2005). Recently, the conversion
f ‘cytoplasmic into ‘viroplasm-associated by interaction with
ypophosphorylated NSP5 has been observed, which is followedby phosphorylation of both molecules (Criglar et al., 2014). Cyto-
plasmic NSP2 also forms complexes with VP1, VP2 and tubulin
(Criglar et al., 2014), making tubulin a component of viroplasms
(Martin et al., 2010), and induces microtubule depolymerization
and stabilization by acetylation (Martin et al., 2010; Eichwald et al.,
2012). Functional proteasomes and components of the autophagic
pathway are essential for viroplasm formation and RV replication
(Contin et al., 2011; López et al., 2011; Arnoldi et al., 2014).
NSP2 forms octamers and has nucleoside triphosphatase, RNA
helix destabilizing and nucleoside diphosphate kinase activities
(Taraporewala et al., 1999; Taraporewala and Patton, 2001, 2004;
Jiang et al., 2006). Grooves in the NSP2 octamer are binding sites
for which NSP5 and ssRNAs compete, thus possibly regulating
the balance between RV RNA translation and replication (Jiang
et al., 2006). NSP5 is a serine- and threonine-rich protein which
occurs in oligomeric forms and becomes hyperphosphorylated
(Torres-Vega et al., 2000; Eichwald et al., 2004; Criglar et al., 2014).
The exact biochemical functions of NSP5 remain to be determined
(Campagna et al., 2007; Contin et al., 2010; Criglar et al., 2014).
NSP4, a transmembrane glycoprotein, is mainly located in the
endoplasmic reticulum (ER) and has multiple functions: (1) It
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erves as an intracellular receptor for DLPs by interacting with VP6
Taylor et al., 1996). (2) It releases Ca2+ from intracellular stores
Tian et al., 1994) by acting as a viroporin (Hyser et al., 2010,
012), thus elevating the intracellular Ca2+ levels needed to sta-
ilize the outer layer of TLPs. The viroporin function was  found
o be due to interaction of NSP4 with the cellular Ca2+ sensor
olecule STIM1 (Hyser et al., 2013). (3) NSP4 forms caps on viro-
lasms and co-localizes with the autophagy protein LC3 (Berkova
t al., 2006). The NSP4-triggered increase of intracellular (Ca2+)
ctivates a kinase-dependent pathway, which leads to autophagy
Crawford et al., 2012; Crawford and Estes, 2013). (4) NSP4 alters
lasma membrane permeability (Newton et al., 1997) and destabi-
izes intercellular junctions (Tian et al., 1996). (5) Most importantly,
SP4 was discovered to act as a viral enterotoxin (Ball et al., 1996):
t is secreted early after RV infection, either as a peptide fragment or
s a whole molecule (Zhang et al., 2000; Bugarcic and Taylor, 2006)
nd interacts with non-infected intestinal cells by integrin 11
nd 21 receptors located at their basolateral plasma membranes
Seo et al., 2008). The activated integrin receptors stimulate intra-
ellular reaction cascades which are correlated with intracellular
a2+ release and diarrhea. NSP4 exists in 3 pools in the infected cell
Berkova et al., 2006): (1) localized in the ER as receptor for DLPs;
2) being secreted by the cell as a soluble component (Zhang et al.,
000; Bugarcic and Taylor, 2006); (3) forming ‘caps’ on viroplasms
Berkova et al., 2006).
The RV NSP3 protein has been found to interact (at its N termi-
us) with the 3′ terminus of viral (+) ssRNA and (at its C terminus)
ith the translation factor eIF4G (bound to the 5′ terminus of
he RNA), thus circularizing the viral RNA and functioning like
he polyA binding protein (PABP) for cellular mRNAs (Piron et al.,
998, 1999; Vende et al., 2000; Groft and Burley, 2002). Since
SP3 can evict the PABP from cellular mRNAs, it prevents cellu-
ar mRNA translation very efﬁciently (Piron et al., 1998; Groft and
urley, 2002). Inhibition of NSP3 expression by siRNA, however,
ainly suppresses its effect on cellular mRNA translation; viral RNA
ranslation is not impaired (Montero et al., 2006). Cellular mRNA
ranslation is inhibited by expressed NSP3 leading to the accumu-
ation of PABP and of the cellular mRNAs themselves in the cell
ucleus (Montero et al., 2006; Harb et al., 2008; Rubio et al., 2013).
SP3 also antagonizes part of the innate immune response (see
elow).
NSP1 is the most variable of all RV proteins. It is likely involved
n host range restriction (Broome et al., 1993; Feng et al., 2013).
 key function of NSP1 is its ability to act as an antagonist of the
nnate immune response (see below).
Viroplasms recruit cellular lipid droplets (LDs) which serve as
nergy store and transport vehicles in the cell (Cheung et al., 2010;
rawford et al., 2013). Analysis of the lipidome of viroplasm-LD
omplexes has conﬁrmed their interaction (Gaunt et al., 2013b).
nterference with LD homoeostasis and blockage of neutral fat
reakdown decrease the number and size of viroplasms and the
roduction and infectivity of viral progeny (Cheung et al., 2010;
rawford et al., 2013; Gaunt et al., 2013a).
.5. RNA packaging, minus strand RNA synthesis and DLP
ormation
Due to their persistence length of 1130 A˚ (Kapahnke et al., 1986),
aked dsRNAs cannot be packaged into core shells. Rather, the 11
ifferent (+) ssRNA segments are reassorted, interact with viral core
roteins (see above) and are then packaged and replicated. It is
ssumed (Trask et al., 2012a) that primary replication complexes
f VP1/VP3/ssRNA interact with a VP2 decamer (most likely involv-
ng NSP5 and NSP2) (Berois et al., 2003), leading to the formation of
ore particles. During this process, the negative charge of the RNA
as to be neutralized by co-packaging of either divalent cations orrch 190 (2014) 75–96 81
spermidine, a cellular trivalent cationic compound (Gouet et al.,
1999; Desselberger et al., 2013). The N-terminal domain of VP2 is
essential for the encapsidation of VP1 (and the attached ssRNA)
(Zeng et al., 1998; Boudreaux et al., 2013). Complex formation with
VP2 is essential for the RdRp activity of VP1, with VP1/VP2 com-
plexes constituting the minimal replicase particles in vitro (Zeng
et al., 1996). The molecular details of the early morphogenesis of
RV particles (core particle formation and RNA replication) are not
well understood. In particular, it is unclear how the packaging of
the correct set of 11 RNA segments into individual particles is con-
trolled. Once formed, core particles are rapidly transcapsidated by
VP6, leading to the synthesis of DLPs. The latter process has been
studied in vitro (Trask and Dormitzer, 2006; Desselberger et al.,
2013).
5.6. Virus particle (virion) maturation and release
RV DLPs, upon leaving the viroplasms, bud through the endo-
plasmic reticulum (ER) for maturation. In this process, NSP4
serves as an intercellular receptor by interacting with VP6 (Taylor
et al., 1996). Within the ER, nascent RV particles are transiently
enveloped, but the envelope is lost when RV particles acquire the
outer layer consisting of VP4 (60 trimers) and VP7 (260 trimers).
(Estes and Greenberg, 2013). The origin, function and loss of the
transitory envelope are not understood. However, it is likely that
VP4 trimers, which form spikes, react with VP6 ﬁrst and are
then embedded in a continuous layer of VP7 trimers (Trask and
Dormitzer, 2006) (Fig. 3). Transcapsidation experiments in vitro
have shown that only by VP4 interacting with DLPs ﬁrst, followed
by interaction with VP7, full infectivity of TLPs can be restored
(Trask and Dormitzer, 2006). Another pool of VP4 interacts with
the cellular plasma membrane (González et al., 2000; Nejmeddine
et al., 2000; Delmas et al., 2007). As described above, by interacting
with DLPs NSP4 has a crucial function in the maturation process:
blockage of NSP4 expression by siRNA leads to RV particle matura-
tion defects (Silvestri et al., 2005), and RV RNA replication is also
inhibited, possibly by the NSP4 fraction interacting with viroplasms
(Berkova et al., 2006). RV TLPs are released from non-polarized cells
(MA104) by lysis (McNulty et al., 1976), but from epithelial cells (e.g.
Caco-2) by a kind of budding process that does not immediately kill
the cell (Gardet et al., 2006).
5.7. Persistent RV infection
In cell culture and in immunocompromised hosts (humans and
other mammalian species) RV infection can become persistent
(Estes and Graham, 1980; Chiarini et al., 1983; Riepenhoff-Talty
et al., 1987; Mrukowicz et al., 1998). The detailed molecular mech-
anisms of this virus–host relationship are poorly understood at
present.
5.8. Growth of RVs in stem cell organoids
Following the achievement of differentiating human stem cell
lines in vitro into intestinal cell-like cultures (human intestinal
organoids) (Spence et al., 2011), it was shown that such cultures
can be infected with RVs, both laboratory strains (SA11) and clinical
isolates (Finkbeiner et al., 2012). The full potential of such cultures
for studying RV replication is in the process of being explored.
5.9. Cellular proteins involved in RV replicationAs obligate cellular parasites viruses require cellular functions
for their replication. Most viruses do not possess the machinery
to translate proteins from their mRNAs and rely on the translation
organelles and functions of the host cell. More recently, a much
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ider involvement of cellular compounds and functions in virus
eplication was uncovered. For RVs those are:
 cellular receptors and co-receptors for adsorption (section V.1),
 cellular endosomes for uncoating of TLPs to DLPs (section V.2),
 interaction of the ‘viral factory’ viroplasms with LDs (Section 5.4),
 interaction of NSP3 with components of the cellular translation
machinery,
 interaction of NSP4 with cellular membranes containing the
intracellular Ca2+ stores (Section 5.4),
 interaction of viral NS proteins with cellular structural proteins
(actin, microﬁlaments),
 interaction of NSP1 with various components of the cellular
innate immune response (see below).
. RV genetics and reverse genetics
RV functions have been explored by genetic studies with sponta-
eous mutants, but mainly by determining reassortment groups of
s mutant collections at the non-permissive temperature. Thus, for
A11 RV, 10 out of the 11 expected reassortment groups have been
dentiﬁed, and 9 of them assigned to individual genome segments
Criglar et al., 2011; Vende et al., 2013).
Several reverse genetics (RG) systems for RVs have been
escribed, but so far they all depend on the presence of a helper
irus and require strong selection conditions. Thus, VP4 genes
native or chimeric) transcribed from a cDNA plasmid have been
escued into viable virus in the presence of neutralizing antibody
irected against the VP4 of the helper virus (Komoto et al., 2006,
011). A dual selection mechanism (use of ts mutants of the helper
irus at the non-permissive temperature, and of siRNA directed
gainst the helper virus gene of interest for engineered reassort-
ent) has been applied to drive single gene RG (Trask et al., 2010b)
Fig. 5). Using this technique, it has been possible to engineer par-
ial gene duplications and heterologous cDNA sequences (encoding
LAG, a hepatitis C virus E2 epitope and an IRES sequence) into the
′ UTR of the NSP2 gene of the SA11 RV (Navarro et al., 2013), thus
pening the potential of creating a recombinant RV that can act as a
iral vector. In addition, rearranged genome segments transcribed
rom cDNA were engineered into helper virus, possibly based on the
referential packaging of rearranged genes (Troupin et al., 2010).
Attempts to establish a helper virus-free, fully tractable and uni-
ersally applicable RG system for RV have so far failed, in contrast
o successful, RNA- or plasmid-only based RG systems for orthore-
virus (Kobayashi et al., 2007) and orbivirus (Boyce et al., 2008).
ollowing the lead of Boyce et al. (Boyce et al., 2008), who  res-
ued infectious bluetongue virus after co-transfection of the 10
ull-length (+) ssRNA transcripts, Richards et al. (Richards et al.,
013) were unable to rescue viable RVs. The main impediment
eemed to be a lack of translation of transfected full-length RV
NAs or cDNAs (with the RV insert downstream from a T7 pro-
oter, in the presence of a fowlpox virus-T7 recombinant) and a
trong cytotoxic effect of transfected RNAs. O’Neill et al. (2013),
entzel et al. (2013) and Wentzel (2014) observed translation of
everal transfected full-length RNA segments, possibly by using
ifferent cell lines, but also recorded a high degree of cytotox-
city which they considered to be caused by an extremely high
timulation of the innate immune response. Despite progress in
btaining translation of transfected RV RNAs, this research group
ould not rescue infectious RV progeny from RNA co-transfections
lone, either. Taken together, work on plasmid-only or transcript-
nly based RG systems for RVs has so far only succeeded in helping
o identify procedural bottlenecks which have to be overcome.
Despite the lack of a nucleic acid-only based RG system, it
as been possible to incorporate in vivo-biotinylated VP6 intorch 190 (2014) 75–96
infectious RV particles (De Lorenzo et al., 2012); the procedure
should be useful for labelling and functional exploration of other
RV structural proteins.
7. Molecular pathogenesis and pathophysiology
RVs mainly infect mature enterocytes at the top of the villi of
the small intestine of mammalian species, where vacuolization
and epithelial loss can be observed, followed by crypt hyperpla-
sia. Although extraintestinal spread of RV occurs frequently as
evidenced by detection of RV dsRNA, RV antigen, and (occasionally)
infectious RV in serum and other host body sites (Blutt et al., 2003;
Blutt and Conner, 2007), the signiﬁcance of these observations for
pathologic ﬁndings in normal (immunocompetent) hosts is con-
troversial (Fenaux et al., 2006; Ramig, 2007; Ramani et al., 2010).
By contrast, in the immunocompromised hosts, RV can replicate
in the liver, the biliary system and the pancreas and be associated
with biliary atresia and pancreatitis (Gilger et al., 1992; Feng et al.,
2008). A striking ﬁnding (in animal models) is the onset of diarrhea
at an early time point when histopathological changes of the small
intestine are absent (Ward et al., 1996), likely due to early action of
NSP4 (Estes and Morris, 1999; Estes and Greenberg, 2013) which
forms oligomers of different size (Bowman et al., 2000; Chacko et al.,
2011). The pathogenesis of RV disease is multifactorial, depending
on the age of host, homology/heterology of virus-host interaction,
and particular viral gene products (VP3, VP4, VP7, NSP2, NSP3,
NSP4; Broome et al., 1993; Ball et al., 1996; Burke and Desselberger,
1996; Estes and Atmar, 2003; Ramig, 2004; Greenberg and Estes,
2009). Using simian (RRV)-mouse (EW) RV reassortants, Feng et al.
(2013) concluded that the genes encoding the mouse VP4 and NSP1
were determinants for efﬁcient replication in suckling mice.
Factors of the disease mechanism are: maladsorption following
destruction of epithelium (Estes and Atmar, 2003), villus ischemia
(Osborne et al., 1991), the action of NSP4, a viral enterotoxin (Ball
et al., 1996; Greenberg and Estes, 2009; Chattopadhyay et al.,
2013), and activation of the enteric nervous system (Lundgren
et al., 2000). Recently, the pathogenesis of the symptom vomiting
has also been elucidated by observations that RV can infect the
enterochromafﬁne cells in the gut and stimulate the production
of 5-hydroxytryptamin (serotonin) which in turn activates vagal
afferent nerves and stimulates brain stem structures controlling
vomiting (Hagbom et al., 2011, 2012).
Biliary atresia (BA) can be induced in newborn mice by RV infec-
tion, leading to obstructive cholangiopathy, the severity of which
depends on the host’s age at the time of infection and also on the
presence and potency of innate immune responses (Mohanty et al.,
2013). In this model, newborn mice can be protected from BA by
passive immunization, achieved either by immunizing the dams
with RV-like particles or by injecting hyperimmune serum into
pubs prior to infection (Hertel et al., 2013).
A relatively novel area of the exploration of gut diseases is the
metagenomic analysis of viruses and other microbes found in the
gut (Finkbeiner et al., 2008; Minot et al., 2012, 2013) and the corre-
lation of their presence with disease. Using this approach, genomes
of viruses can be discovered the particles of which have not been
previously observed nor isolated by cell culture. So far, mainly DNA
viruses, many of them bacteriophages, were analyzed. Protocols to
discover both DNA and RNA viruses in fecal specimens have been
developed (Sachsenroder et al., 2012), and applications to the anal-
ysis of the full human gut virome have started (Kapusinszky et al.,
2012; Phan et al., 2012; Ryan, 2013). It will be important to know
whether and to what extent the human gut microbiome, including
the virome, may  inﬂuence the pathogenesis of chronic gut diseases
(such as Crohn’s disease and colitis ulcerosa) (Virgin, 2014). Using
the gnotobiotic piglet model of human RV infection and disease, it
U. Desselberger / Virus Research 190 (2014) 75–96 83
Fig. 5. Reverse genetics of a gene 8 recombinant rotavirus using a dual selection system. (A) Diagram of the recombinant gene 8 cDNA. A minimal T7 RNA polymerase
promoter (T7P) initiates transcription of an SA11 gene 8 (+) RNA with an authentic 5′ end. The g8D RNAi target site was  engineered to prevent targeting of the recombinant
mRNA. Cleavage by a modiﬁed HDV ribozyme (Rbzm) generates the authentic 3′ end. (B) Diagram of the reverse genetics method. COS-7 cells are infected with rDIs-T7pol
(VV-T7)  (i) and transfected with the recombinant gene 8 plasmid (pBS-SA11g8R) (ii) before infection with the tsE helper virus at 30 ◦C (iii). The recovered virus stock contains
both  tsE helper virus and the tsE/SA11g8R virus. Passage at 39 ◦C in MA104-g8D cells (iv) allows rapid isolation of the tsE/SA11g8R virus (v).
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as observed that properly dosed probiotic lactic acid bacteria can
nhance the Th1 and Th2 cytokine responses and partially prevent
V-induced injuries to the gut epithelium (Azevedo et al., 2012; Liu
t al., 2013).
. Immune responses
.1. RV-speciﬁc humoral and cell-mediated immune responses
Upon RV infection, acquired immune responses are elicited,
oth from B cells producing antibodies directed against virus-
peciﬁc proteins, and from T cells recognizing T cell-speciﬁc RV
pitopes on the surface of infected cells in complexes with MHC
lasses I and II antigens. Many antibodies directed against VP7 and
P4 on the surface of RV particles are neutralizing (NAb) in vitro
nd protective in vivo, as demonstrated by passive transfer in mice
nd gnotobiotic piglets as animal models (Ofﬁt, 1994; Feng et al.,
997; Franco and Greenberg, 1997; Yuan and Saif, 2002; Jiang et al.,
002). Passive transfer of RV-speciﬁc CD8+ T cells has also shown
o be protective (Ofﬁt, 1994). Transplacentally acquired RV-speciﬁc
ntibodies likely protect newborns from infection (Ray et al., 2007)
nd interfere with immune responses to RV vaccination (Johansson
t al., 2008; Appaiahgari et al., 2014). The availability of various
nockout mutant mice has permitted researchers to dissect the rel-
tive contributions of humoral and cellular immune responses to
rotection: while RV-speciﬁc T cells help eliminate RV after primary
nfection, it is the RV-primed memory B cells which provide more
ong-term protection (Franco et al., 2006). Humoral antibodies
oosted after repeated infection are directed against both serotype-
peciﬁc and cross-reactive epitopes on VP4 and VP7 molecules, thusalso providing heterotypic protection (Franco et al., 2006). Plasma-
cytoid dendritic cells were found to be necessary and sufﬁcient to
induce B cell activation after RV infection in mice (in vivo) and in
human cells (in vitro) (Deal et al., 2013). Human RV-speciﬁc CD4+ T
cells circulating in the blood express the intestinal homing recep-
tor 47 (Gonzalez et al., 2003; Weitkamp et al., 2005; Parra et al.,
2014). However, protection from RV infection is not entirely corre-
lated with the concentration of VP4- and VP7-speciﬁc NAbs. Upon
natural infection by or vaccination with RV, infants and young chil-
dren develop antibodies against other structural (VP6, VP2) and
nonstructural (NSP4) proteins. VP6-speciﬁc antibodies do not neu-
tralize in vitro, but were shown to be protective in vivo (Burns
et al., 1996), when VP6-speciﬁc antibodies of the IgA class were
applied. It was suggested and has recently been proven that VP6-
speciﬁc IgA antibodies are taken up (‘transcytosed’) by epithelial
gut cells through J protein receptors at the basolateral membrane
and form complexes with new DLPs released from viroplasm, thus
preventing their maturation to TLPs (‘intracellular neutralization’)
(Desselberger, 1998; Schwartz-Cornil et al., 2002; Feng et al., 2002;
Corthésy et al., 2006; Aiyegbo et al., 2013; Sapparapu et al., 2013).
However, it has also been shown that mice and patients who  are
IgA-deﬁcient eliminate RV after infection, probably due to a com-
pensatory IgG protective immunity (O’Neal et al., 2000). Passive
transfer of NSP4 antibody has produced some protection in mice
(Hou et al., 2008), but actively acquired NSP4 antibody does not
protect gnotobiotic piglets from a challenge with RVA (Yuan et al.,
2004). Prospective studies have shown that, after 1 or 2 natu-
ral RV infections, children appear to be highly protected against
severe disease following infection by various, also heterotypic, RVs
(Velázquez et al., 1996).
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Fig. 6. Modulation of the host innate immune system by RV infection. After entry
into cells, actively transcribing RV is recognized by receptors RIG-I and MDA-5
which activate the transcription factors IRF3 and NF-kB; in turn those migrate to
the  nucleus and stimulate interferon (IFN) and IFN stimulatory genes (ISG). The
viral NSP1 interacts with IRF3 and other cellular proteins (NF-B a.o.), which are
then degraded. Interferon is secreted and, by binding to IFN receptors, activates
transcription factors STAT-1, STAT-2, and IRF9 which in turn further stimulate IFN
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.2. Innate immune responses
RV infection immediately triggers various mechanisms of innate
mmune responses (IIR), which occur earlier than acquired RV-
peciﬁc immune responses, at least after primary infection (Angel
t al., 2012) (Fig. 6). Many IIRs appear to be RV strain-speciﬁc
nd also cell type-speciﬁc (Feng et al., 2009). At present it is not
ully clear to what extent the IIRs after RV infection modify dis-
ase. It has been shown that the RV NSP1 is able to interact with
he following cellular proteins: interferon (IFN) regulatory factors
IRF) 3 (Graff et al., 2002, 2007; Barro and Patton, 2005; Sen et al.,
011), -transducin repeat containing protein (-TrCP0) (Graff
t al., 2009; Qin et al., 2011), melanoma differentiation-associated
ene 5 (MDA5)/mitochondrial antiviral signaling protein (MAVS)
Broquet et al., 2011; Sen et al., 2011; Nandi et al., 2014), the tumor
uppressor protein p53 (Bhowmick et al., 2013) and the TNF recep-
or associated factor 2 (TRAF2) (Bagchi et al., 2013), leading to their
roteasomal degradation and thus preventing or down-regulating
he early triggering of an IFN response. RV NSP1 also induces down-
egulation of IRF5 and IRF7 (Barro and Patton, 2007) and targets
etinoic acid-inducible gene I (RIG-I) (Broquet et al., 2011) which,
owever, is downregulated by a proteasome-independent pathway
Qin et al., 2011). NSP1 interacts with IRF3 by binding to the dimeri-
ation domain of the protein (Arnold et al., 2013a, 2013b). Rotavirus
nfection also inhibits STAT1 phosphorylation and STAT1/STAT2
ranslocation to the nucleus and thereby the establishment of an
FN-induced ‘antiviral state’ (Holloway et al., 2009, 2014; Holloway
nd Coulson, 2013; Sen et al., 2014). In addition, the C-terminal
omain of the RV capping enzyme, VP3, has recently been shown
o contain a phosphodiesterase which cleaves 2′,5′-oligoadenylate,
hereby preventing activation of RNase L and blocking a potent
IR host cell response (Zhang et al., 2013). RIG-I was  found to
ct as a cytoplasmic sensor for ssRNAs extruded from transfected
LPs (Uzri and Greenberg, 2013). NSP1 targets the pro-apoptotic
ellular protein p53, leading to its proteasomal degradation andrch 190 (2014) 75–96
thus delaying cell death during the early stages of RV replication
(Bhowmick et al., 2013).
Combined ﬂow cytometry and single cell multiplex RT-PCR
allowed the dissection of the IIRs of RV-infected and bystander
intestinal epithelial cells in mice infected with a homologous RV;
heterogeneity of induction and subversion of early IIRs was discov-
ered (Sen et al., 2012).
Rotavirus infection causes more severe disease in mice deﬁcient
in IFN signaling (Vancott et al., 2003; Feng et al., 2008, 2011). Inter-
feron production is a dominant IIR in RV-infected pigs (González
et al., 2010) and humans (Wang et al., 2007). Human plasmacytoid
dendritic cells do not replicate RV, but initiate a brisk IFN response
that may  stimulate B cell responses (Deal et al., 2013).
The virus-encoded nonstructural protein NSP4 secreted from
RV-infected cells was  shown to induce the synthesis of pro-
inﬂammatory cytokines from murine macrophages (Ge et al., 2013).
Human RV-speciﬁc CD4+ and CD8+ T cells and B cells express the
gut homing receptor 47 (Rojas et al., 2003, 2008). Thus, RV
components interact by various mechanisms with molecules and
pathways of the cellular IIR.
8.3. Correlates of protection
In general, there is a correlation between the presence of cer-
tain levels of humoral RV-speciﬁc antibody and protection (e.g.
RV-speciﬁc copro IgA of >1:80; RV-speciﬁc serum IgA of >1:200;
RV-speciﬁc serum IgG of >1:800) (Matsui et al., 1989a, 1989b; Ofﬁt,
1994). The signiﬁcance of RV-speciﬁc serum IgA antibody levels as
correlates of protection has been claimed (Blutt et al., 2012; Patel
et al., 2013; Cheuvart et al., 2013; Blutt and Conner, 2013), but this
remains controversial (Angel et al., 2012). However, since there is
a lack of correlation between relatively low Nab titers after natural
RV infection or vaccination and high levels of protective immu-
nity achieved, additional factors of importance for protection are
likely (Desselberger and Huppertz, 2011). Interestingly, both cur-
rently licensed RV vaccines are highly efﬁcacious and effective in
countries of temperate climate (see below), although the correlates
of protection are incompletely deﬁned (Franco et al., 2006; Angel
et al., 2007; Desselberger and Huppertz, 2011).
9. Clinical symptoms and differential diagnosis, laboratory
diagnosis and treatment
RV infections can remain asymptomatic (see below) or lead to
acute gastroenteritis (AGE) with mild to severe diarrhea, vomiting
and various degrees of dehydration. The body temperature is often,
but only moderately, elevated. Vomiting precedes diarrhea and
lasts for a shorter time period (3 vs 5 days). A massive electrolyte
imbalance leads to often severe dehydration. Death from RV dis-
ease is mainly due to severe dehydration and cardiovascular failure.
Whereas death from RV-associated disease is rare in developed and
semi-developed countries, mainly due to the timely availability of
rehydration measures, it is a frequent outcome in countries of sub-
Saharan Africa and southeast Asia (Tate et al., 2012). Upon natural
infection or (inadvertent) vaccination, children with severe com-
bined immunodeﬁciency (SCID) can develop a chronic RV infection
and disease (Desselberger, 1996; Patel et al., 2010). In chroni-
cally infected children, RVs with ‘unusual’ RNA migration patterns
emerge, due to genome rearrangements (Desselberger, 1996).
The diagnosis of RV infection is by electron microscopy or ELISA
(Brandt et al., 1981), and more recently by RT-PCR (Gouvea et al.,
1990; Gentsch et al., 1992; Gómara et al., 2000; Iturriza-Gómara
et al., 2004). Of those procedures, ELISA is applied most frequently
in the routine diagnostic laboratory (due to the ease of use and
speed of obtaining a result). However, RT-PCR, which is highly
sensitive and speciﬁc (Richardson et al., 1998) and also suitable
 Resea
f
2
D
t
c
F
t
a
v
a
r
t
H
R
i
c
v
f
s
o
c
v
1
p
S
t
o
m
e
a
e
v
w
d
b
p
c
a
2
w
p
R
e
(
a
2
t
R
a
T
t
s
2
b
(
e
1
cU. Desselberger / Virus
or genotyping (Fischer and Gentsch, 2004; Iturriza-Gómara et al.,
004), has become the ‘gold standard’ of diagnostic discovery.
ue to continuous genomic drift by point mutations (see below)
he primers used for genotyping have to be changed periodi-
ally (Iturriza-Gómara et al., 2000, 2004; Simmonds et al., 2008).
or the differential diagnosis of disease causes, the main viruses
o be considered are human caliciviruses (norovirus, sapovirus),
stroviruses and (less frequently) enteric adenoviruses and Aichi
irus. Many of those can be searched for by multiplex RT-PCR
ssay (e.g., Liu et al., 2011). Other viruses infecting the gut and
emaining mostly asymptomatic are different enteroviruses and, in
he immunocompromised, picobirnaviruses, cytomegalovirus and
IV (Desselberger and Gray, 2013).
In an internally controlled study, the genomes of G10P[11]
Vs isolated from 20 asymptomatic and 19 symptomatic neonates
n Vellore, India, in 2003/2004, were determined by dideoxynu-
leotide (Sanger) and next generation sequencing and found to be
irtually identical. Most importantly, no nt or amino acid (aa) dif-
erences were found which were correlated with asymptomatic or
ymptomatic infection (Libonati et al., 2014). It was concluded that
ther, poorly deﬁned factors would determine the appearance of
linical symptoms.
The treatment consists mainly of rehydration (orally or intra-
enously) (American Academy of Pediatrics, 1996; Desselberger,
999; Atia and Buchman, 2009; Guarino et al., 2012). Various com-
ositions of oral rehydration salts (ORS) have been devised (CHOICE
tudy Group, 2001; Atia and Buchman, 2009), and rice-based solu-
ions are also successfully applied (Pizarro et al., 1991). The use
f loperamide, anticholinergic drugs and adsorbents is not recom-
ended (American Academy of Pediatrics, 1996). Racecadotril, an
ncephalinase inhibitor suppressing the enteric nervous system
ctivated after RV infection (Lundgren et al., 2000; Salazar-Lindo
t al., 2000), granisetron, a serotonin receptor antagonist, and
asoactive intestinal peptide antagonists (Kordasti et al., 2004)
ere also found to be beneﬁcial in decreasing the severity of acute
iarrhea. Oral solutions containing high concentrations of RV anti-
ody were found to be beneﬁcial therapeutically, as well as a
reventative measure (Saulsbury et al., 1980; Ebina, 1996).
Recently, llama-derived single-chain antibody fragments spe-
iﬁc for RV VP6 were shown to be broadly cross-reactive in vitro
nd to decrease virus shedding in infected mice (van der Vaart et al.,
006; Garaicoechea et al., 2008; Aladin et al., 2012). This antibody
as also efﬁcacious in decreasing RV replication in gnotobiotic
iglets (Vega et al., 2013) and had a moderately beneﬁcial effect on
V disease in humans (Sarker et al., 2013; Kang, 2013; Tokuhara
t al., 2013). The antibody fragment that is of only 15 kDa size
Joosten et al., 2003) remained active after long-term (>1 year) stor-
ge and was resistant to heating at 94 ◦C for 90 min  (Tokuhara et al.,
013). The llama antibody fragment was expressed at high levels in
ransgenic rice (MucoRice-ARP1); in pilot studies, it suppressed the
V load in both immunocompetent and immunodeﬁcient mice and
lso conferred protection from RV infection (Tokuhara et al., 2013).
his and similar antibody preparations have a realistic potential for
herapeutic and prophylactic use in humans (Kang, 2013).
Other therapeutic approaches consist of the use of the broad
pectrum antiviral nitazoxanide (Rossignol et al., 2006; Teran et al.,
009; La Frazia et al., 2013) and – supported by work with gnoto-
iotic piglets (Azevedo et al., 2012; Liu et al., 2013) – of probiotics
Fang et al., 2009; Grandy et al., 2010; Corrêa et al., 2011; Ciccarelli
t al., 2013).0. Molecular epidemiology and mechanisms of evolution
Rotaviruses cause 5–10% of all cases of AGE in infants and young
hildren of <5 years of age, and 30% of RV disease is severe enough torch 190 (2014) 75–96 85
require treatment in primary care centers or hospitals (Malek et al.,
2006; Parashar et al., 2006; Liu et al., 2012). In the US before vacci-
nation, RVs caused 3 million disease episodes per annum,  requiring
500,000 visits to a medical doctor and 60,000 hospitalisations, but
leading to only 20–40 deaths (Fischer et al., 2007; Esposito et al.,
2011). Similar numbers were found to be valid in Europe, except
that the number of deaths was  about 200 (Soriano-Gabarró et al.,
2006; Van Damme  et al., 2007). In sub-Saharan African and in some
south Asian countries, RV disease is associated with a high mortality
(Parashar et al., 2009; Tate et al., 2012).
Despite the large genomic and antigenic diversity of RVs (see
above), globally only a small number of RV types have prevailed
in humans during the past 3 decades: RVs of types G1P1A[8],
G2P1B[4], G3P1A[8], G4P1A[8], and more recently G9P1A[8] and
G12P1A[8] have co-circulated at high frequency, contributing
80–90% of all RV infections in North America, Europe and Australia
(Gentsch et al., 2005; Santos and Hoshino, 2005; Iturriza-Gómara
et al., 2011). By contrast, in African, Asian and South American
countries, other genotypes such as G5, G6 and G8 are more preva-
lent (Todd et al., 2010; Mwenda et al., 2010; da Silva et al., 2011;
Kang et al., 2013; Luchs and Timenetsky, 2014). Regarding the over-
all prevalence estimates of particular RVA genotypes, the problem
of sampling bias should not be underrated.
With the advent of RV genotyping by RT-PCR (Gouvea et al.,
1990; Gentsch et al., 1992), detailed studies of the molecular
epidemiology of RVs have become possible. Genotyping has an
enormous value for assessing the evolution and epidemiological
pathways of RVs in humans, mammals and birds (Matthijnssens
et al., 2011b; Matthijnssens and Van Ranst, 2012). However, the
importance of RV typing for success of vaccination may  have been
overestimated. Among other facts, the broad heterotypic efﬁcacy
and effectiveness of a monovalent RV vaccine (Rotarix®) calls this
‘dogma’ into question (see below). Outbreak of AGE caused by
species B RVs have been observed in China (Hung et al., 1983, 1984),
and individual cases of species B RV infections have been detected
in Bangladesh and India (Kelkar and Zade, 2004; Lahon et al., 2013).
RVC infections are mostly asymptomatic or clinically mild, but can
cause diarrhea in adults (Nilsson et al., 2000). Infections with RVD,
RVF and RVG are mainly discovered in birds. Infections with RVH
were detected in piglets (Wakuda et al., 2011; Molinari et al., 2014;
Marthaler et al., 2014) and in humans (Jiang et al., 2008b).
RVs are very contagious for the following reasons: (1) a low
number of virus particles at a low ratio of (number of virus
particles/infectious units) sufﬁces to productively infect a sus-
ceptible individual (Ward et al., 1986; Graham et al., 1987); (2)
rotavirus particles are shed in large numbers in feces (up to 1011
particles/ml) during the acute stage of the infection (Ward et al.,
1984) or for longer periods by infected immunocompromised
hosts (Patel et al., 2010); and (3) RV particles are very resistant
to environmental conditions (temperature, pH, etc.; Estes et al.,
1979; Keswick et al., 1983). The transmission is usually fecal–oral,
the incubation period is short (1–2 days). Attendance of day child
care centers is a risk factor to acquire a symptomatic RV infection
(Pickering et al., 1988; Dennehy et al., 2006). Small RV epidemics
among the elderly (in old people’s homes, geriatric wards, etc.)
have been observed (Hrdy, 1987). Nosocomial RV infections are
frequent and difﬁcult to eliminate (Gleizes et al., 2006).
The evolution of RVs has been elucidated by widespread
genome-wide RT-PCR genotyping supported by cDNA sequencing
(Matthijnssens and Van Ranst, 2012). Several mechanisms were
identiﬁed (Iturriza-Gomara et al., 2003):- frequent point mutations in all RNA segments, either sporadically
occurring or sequentially accumulating (Blackhall et al., 1996;
Iturriza-Gómara et al., 2000; Arista et al., 2005; Simmonds et al.,
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2008; Martínez-Laso et al., 2009; Ianiro et al., 2013; Hemming
and Vesikari, 2013a, 2013b; De Grazia et al., 2014);
 genome reassortment occurring in doubly infected individual
cells and organisms in vivo (Iturriza-Gómara et al., 2001), often
involved in zoonotic transmission (Steyer et al., 2008; Martella
et al., 2010; Todd et al., 2010; Matthijnssens et al., 2011b; Papp
et al., 2013; Mullick et al., 2013; Soma et al., 2013; Cowley et al.,
2013; Luchs and Timenetsky, 2014);
 genome rearrangements, consisting of partial duplications or
deletions of nt sequences of individual segments, a special form
of recombination (Pedley et al., 1984; Desselberger, 1996; Kojima
et al., 1996, 2000);
 true genome recombination involving several segments (Parra
et al., 2004; Phan et al., 2007; Cao et al., 2008; Martínez-Laso
et al., 2009; Donker et al., 2011; Jere et al., 2011);
 several of the aforementioned mechanisms acting in combina-
tion.
The main mechanisms appear to be point mutations that occur
ontinuously due to the high error rate of the RV RdRp (Blackhall
t al., 1996) and genome reassortments. Animal RVs can also be
irectly transmitted to humans (Soma et al., 2013; Steyer et al.,
013).
1. Prevention: development and universal application of
V vaccines, issues arising from present RV vaccination
rograms
Since RVs were discovered as an important enteric pathogen
n children more than 40 years ago, scientists and clinicians have
oined forces to develop a rotavirus vaccine. From studies on
nimal models it had become evident that protection against RV
isease can be achieved by passive transfer of RV-speciﬁc immune
esponse products (antibodies, T cells) or by vaccination (Ofﬁt et al.,
986a, 1986b; Ofﬁt, 1994; Franco et al., 2006; Desselberger and
uppertz, 2011). Prospective observations of young children have
hown that: (1) primary RV infection occurred mostly during the
rst year of life and was generally symptomatic; (2) reinfections
ith RVs during the ﬁrst 2–3 years of life were frequent but rarely
ccompanied by AGE (even when infection occurred by RVs of
/P genotypes which differed from those of the original infection)
Velázquez et al., 1996); (3) the protection achieved after repeated
atural infections was associated with the presence of RV anti-
odies in serum and, more importantly, in the gut (IgA antibodies)
Coulson et al., 1990, 1992). Thus, RV disease in humans was ﬁrmly
ecognized as being vaccine-preventable. Initially, live-attenuated
accines were developed since they seemed optimal in mimicking
 sequence of repeated natural infections with the result of pro-
ection from severe disease (Jennerian approach) (Kapikian et al.,
996). Initial promising results with a live attenuated bovine RV
accine (strain RIT 4237) in Finland could not be reproduced by
rials in developing countries, and work on this vaccine candidate
as discontinued (Senturia et al., 1987). Another bovine RV, the
C3 strain, and a simian RV, RRV, were similarly inefﬁcacious or of
ariable efﬁcacy in their monovalent form (Bernstein et al., 1990;
eorges-Courbot et al., 1991). A modiﬁed Jennerian approach
as used by developing a quadrivalent vaccine that consisted of a
ixture of the attenuated RRV (G3P7[5]) and of mono-reassortants
ontaining the genes encoding VP7 of the human G1, G2 and G4
enotypes in the genetic background of the other 10 RNA segment
f the RRV strain (Kapikian et al., 1996). The quadrivalent, RRV-
ased human reassortant vaccine was efﬁcacious in several large
hase III trials (Santosham et al., 1997; Pérez-Schael et al., 1997;
oensuu et al., 1997). Based on these results the vaccine was  licensed
nd produced under the name of RotaShield® (Wyeth Lederlerch 190 (2014) 75–96
Vaccines) in 1998. During 1998/99 it was applied as a universal
mass vaccination (UMV) to more than 1 million children in the
USA. However, when cases of gut intussusception (IS) occurred
in temporal association with RV vaccination, postponement of
the RV UMV  was  recommended by CDC and AAP (CDC, 1999).
In follow-up investigations, a vaccine-attributable risk of gut IS
of approximately 1:2500 was estimated (Murphy et al., 2001),
which led to the voluntary discontinuation of vaccine production
by the manufacturer. A considerable controversy over the size of
the vaccine-attributable risk of gut IS ensued (Peter and Myers,
2002; Murphy et al., 2003a, 2003b; Haber et al., 2004; Glass et al.,
2004; Bines, 2005; Simonsen et al., 2005; Matson, 2006), leading
to a signiﬁcantly lower estimate (1:10,000 or lower), questioning
the wisdom of the recommendation to discontinue the use of
the quadrivalent vaccine and raising the issue of the ethics of
withholding the vaccine from developing countries in which
mortality from RV disease is high (Weijer, 2000).
Following this backlash, extensive efforts were made to develop
alternative RV vaccines. One of them was  a live-attenuated mono-
valent (G1P1A[8]) vaccine candidate, derived from the human RV
isolate 89–12 and attenuated by serial passage in cell culture. In
a large phase III clinical trial (Ruiz-Palacios et al., 2006), this vac-
cine was found to be highly efﬁcacious against severe RV disease
caused by the homologous RV strain and also heterologous strains
such as G3P[8], G4P[8], and also by G2P[4], although to a slightly
lesser extent (Vesikari et al., 2007). The vaccine was licensed for
universal vaccination of infants in 2005, and since then in many
countries throughout the world (produced as ‘Rotarix®’ by Glaxo-
SmithKline, also termed RV1). Simultaneously, a pentavalent, live
attenuated vaccine was  developed, using the bovine RV WC3  strain
(G6P7[5]) as a genetic backbone for 5 mono-reassortants which
individually carried the genes encoding the human VP7 types G1
to G4 and the human VP4 type P[8] (produced as ‘RotaTeq®’ by
Merck, also termed RV5). This vaccine also underwent a very suc-
cessful phase III clinical trial (Vesikari et al., 2006) and was licensed
from 2006 onwards in many countries throughout the world.
In post-marketing studies both vaccines were found to be
highly effective (with protection rates of 70 to >90%) in developed
countries (Patel and Parashar, 2009; Boom et al., 2010; Vesikari
et al., 2010a, 2010b; Anderson et al., 2011; Buttery et al., 2011b;
Giaquinto et al., 2011; Quintanar-Solares et al., 2011; Tate et al.,
2011a, 2011b, 2013; Tregnaghi et al., 2011; Desai et al., 2012; Payne
et al., 2013a; Cortese et al., 2013; Gastan˜aduy et al., 2013; Rha et al.,
2014; Leshem et al., 2014), signiﬁcantly decreasing RV-associated
AGE necessitating visits to medical practitioners and hospitaliza-
tion, and in some instances also decreasing mortality from the
condition (Richardson et al., 2010; Gastan˜aduy et al., 2013). There
is no clear difference in efﬁcacy between the two  vaccines. As a sur-
prising but welcome side effect, ‘herd immunity’ in non-vaccinated
children was observed (Yi and Anderson, 2013; Anderson et al.,
2013; Dennehy, 2013; Leshem et al., 2014).
There remains a very small vaccine-attributable risk for IS for
both vaccines, at approximately 1:50,000 or less, which, however, is
exceeded by the beneﬁts of the vaccines (Buttery et al., 2011a; Patel
et al., 2011; Greenberg, 2011; Haber et al., 2013; Carlin et al., 2013;
Parashar and Orenstein, 2013; Glass and Parashar, 2014; Weintraub
et al., 2014; Yih et al., 2014).
In contrast to the high effectiveness of RV vaccination in devel-
oped countries, in some middle and low income countries, such as
Mexico, Nicaragua, Malawi, South Africa, Kenya, Mali, Bangladesh
and Vietnam, the efﬁcacy of the vaccine was found to be substan-
tially (20–30%) lower (Armah et al., 2010; Madhi et al., 2010; Zaman
et al., 2010) for reasons that are at present not fully understood
(Lopman et al., 2012; Glass et al., 2014). One factor may  be vita-
min  A deﬁciency, as experimentally explored in gnotobiotic piglets
(Vlasova et al., 2013; Chattha et al., 2013; Kandasamy et al., 2014).
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ince the mortality from RV-associated AGE is highest in the low
ncome countries (Tate et al., 2012), WHO  recommends since 2009
hat RV vaccination should be carried out in all countries, accepting
he relatively lower vaccine effectiveness in low income countries
SAGE, 2009; WHO, 2013).
The ﬁnding of porcine circovirus type 1 and 2 DNA, detected
n the two licensed vaccines by metagenomic techniques, was ini-
ially a shock, but then investigated and not found to be harmful for
umans, and the use of the vaccines continues (Victoria et al., 2010;
cClenahan et al., 2011; Dubin et al., 2013; Esona et al., 2014).
Although the monovalent RV1 vaccine is highly effective against
eterotypic G2P[4] RVs, the proportion of G2P[4]-associated AGE
as higher in vaccinated than in unvaccinated hospitalized chil-
ren (Matthijnssens et al., 2014). Others did not ﬁnd a signiﬁcant,
accine-attributable change in the prevalence of particular RV
enotypes (Dennehy, 2013; Hemming and Vesikari, 2013a; Peláez-
arvajal et al., 2014; Donato et al., 2014). To obtain more clarity
bout this problem, the post-marketing surveillance of RV strains
nd genotype prevalence is continuing.
Since both RV vaccines contain live attenuated virus, it is not
urprising that RV vaccine strain reassortants (between both RV
accine strains and vaccine and wt strains which had arisen during
atural co-circulation) were discovered (Bucardo et al., 2012; Boom
t al., 2012; Hemming and Vesikari, 2013b).
Another live attenuated RV, the human-bovine natural reas-
ortant 116E (G9P8[11], originally isolated from asymptomatically
nfected newborns in India), has been tested in a phase III clinical
rial in India, and an efﬁcacy against severe RV disease of 56% was
ecorded (Bhandari et al., 2014) which is comparable with that of
he R1 and R5 RV vaccines in middle and low income countries (see
bove).
Due to the high effectiveness of RV vaccine programs, the pre-
ominant cause of hospitalization of children with AGE are now
orovirus infections (Koo et al., 2013; Payne et al., 2013b; Hemming
t al., 2013; Bucardo et al., 2014).
As alternatives to live attenuated vaccines, inactivated virus
articles (Jiang et al., 2008a, 2013; Wang et al., 2010), virus-like
articles (VLPs) expressed from baculovirus recombinant-infected
nsect cells (Crawford et al., 1994; Conner et al., 1996; O’Neal
t al., 1997; Ciarlet et al., 1998; Crawford et al., 1999; Azevedo
t al., 2013) or yeast (Rodríguez-Limas et al., 2014), and DNA-based
accines (Herrmann et al., 1996) are being explored. Rotavirus
P6 nanotubules, also in combination with norovirus VLPs, are
romoted as candidates for novel RV vaccines (Tamminen et al.,
013; Lappalainen et al., 2013; Rodríguez et al., 2013; Pastor et al.,
014). Experimentally, VP6-speciﬁc single chain antibodies (of only
5 kDa MW)  produced in llamas have been shown to have some
ross-protective effect in vitro (Garaicoechea et al., 2008) and in vivo
Garaicoechea et al., 2008; Vega et al., 2013).
2. Perspectives of future basic and translational research
Major progress in basic RV research will depend on the estab-
ishment of a tractable, helper virus-independent, plasmid (cDNA)-
r RNA-only based reverse genetics system for RVs.
Based on the data reviewed, the following topics will require or
re likely to attract research attention in the future:
 the 3D structure of the dsRNA segments packaged in the RV core
and their potential interaction with the core shell VP2;
 the different receptor speciﬁcities of different RV strains;
 details of the interaction of viroplasms with lipid droplets;
 the mechanisms controlling assortment/reassortment of 11 RNA
segments in replication complexes (i.e. RNA/RNA interactions);
 the mechanisms controlling RV RNA packaging;rch 190 (2014) 75–96 87
- the formation and loss of temporary enveloped RV particles in the
ER during the viral maturation process;
- the potential of intestinal organoid cell cultures for the study of
RV replication;
- the factors (mutations) determining RV pathogenicity and viru-
lence;
- the molecular basis for host range and organ/cell speciﬁc viral
replication;
- the signiﬁcance of the different arms of the immune response in
establishing protection against RV disease;
- the full identiﬁcation of the correlates of protection against RV
disease;
- the factors determining RV spread;
- the reasons for decreased efﬁcacy of RV vaccines in reserve-
strapped settings and areas of low socioeconomic conditions;
- the further evolution of human RVs under the condition of uni-
versal mass vaccination against RV disease;
- the development of alternative (non-live attenuated) RV vaccine
candidates;
- the development of RV antivirals.
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